Source: Eur Respir J, 50 (3) 1701582; 10.1183/13993003.01582-2017
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
James D. Chalmers, Holly R. Keir. 10 years since TORCH: shining a new light on the risks of inhaled corticosteroids in COPD. Eur Respir J, 50 (3) 1701582; 10.1183/13993003.01582-2017

Member's Comments

No comment yet.

Related content which might interest you: Airways diseases: influential developments in the past 5 years Source: Annual Congress 2005 - PG14 - Moving on from the Millennium: developing trends in respiratory medicine (jointly organised with ACCP) Year: 2005 Children with mild asthma: do they benefit from inhaled corticosteroids? Source: Eur Respir J 2002; 20: 1470-1475 Year: 2002 A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD Source: Annual Congress 2013 –Risk factors for COPD and lung function decline Year: 2013 What to use INSTEAD of inhaled corticosteroids in COPD? Source: Eur Respir J 2014; 44: 1391-1393 Year: 2014 Annual systemic and inhaled corticosteroid exposures in US patients =4 years with asthma Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Less than 20% of COPD patients persist with long-acting inhaled drugs for at least three years Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results Source: Eur Respir J 2009; 34: 641 Year: 2009 The effect of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A real practice analysis in Italy Source: International Congress 2014 – Prevalence of COPD and mortality from COPD Year: 2014 Asthma control and medication use five years after early or delayed introduction of inhaled corticosteroids in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003 Is there a problem with inhaled corticosteroid use in COPD? Source: Virtual Congress 2020 – Airway diseases Year: 2020 The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype Source: International Congress 2015 – COPD and lung function: risk factors and outcomes Year: 2015 Treatment with inhaled corticosteroids (ICS) in patients with COPD: possible way of optimisation Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Treatment with inhaled corticosteroids (ICS), smoking and asthma control in real clinical practice Source: Annual Congress 2010 - Pharmacological treatment in primary care Year: 2010 Use of long acting bronchodilators and inhaled corticosteroids within 30-days of discharge in older adults hospitalized for AECOPD Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015 Low dose inhaled corticosteroids (ICS) and short-acting beta-agonists (SABA) or long-acting beta-agonists (LABA) need in children and adolescents with asthma steps 1 and 2: what is the evidence? Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents? Year: 2020 Efficacy and safety of inhaled corticosteroids in combination with a long-acting beta2-agonist in asthmatic children under age 5 Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016 Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Intermittent versus daily inhaled corticosteroids (ICS) in children and adults with mild persistent asthma: A Cochrane review Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Inhaled corticosteroids in COPD: the clinical evidence Source: Eur Respir J 2015; 45: 525-537 Year: 2015